Friday, 16 October 2026European Markets

ID Logistics Trades at 4x Its DCF Value as Analyst Targets Diverge

ID Logistics Group trades at €354.0 on Euronext Paris — 4.06 times its DCF intrinsic value of €87.24. If market sentiment shifts toward fundamental-based pricing, implied downside exceeds 75%. Analyst consensus targets €482.57, moving further from the DCF floor, not toward it.

LM Salvado
LM Salvado

May 19, 2026

ID Logistics Trades at 4x Its DCF Value as Analyst Targets Diverge
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

ID Logistics Group trades at significant capitalon Euronext Paris — 4.06 times its discounted cash flow intrinsic value of significant capital.1

The French mid-cap warehousing and supply chain operator has built a broad European footprint. Its market price now implies a premium that DCF fundamentals do not support.1

The gap is wide. If sentiment shifts toward fundamental-based pricing, the implied downside exceeds 75%.1 That would draw the stock back toward the significant capitalDCF estimate.

Analyst consensus points in the opposite direction. The consensus target sits at significant capital— above the current price and far above the DCF model.1 That divergence suggests sell-side forecasts embed growth assumptions the DCF framework does not validate.

DCF models are sensitive to inputs: discount rates, terminal growth assumptions, and free cash flow projections. A company with strong competitive positioning in European logistics can legitimately trade above a baseline DCF estimate. But a 4x multiple over intrinsic value is a wide buffer to justify.

ID Logistics operates in a sector under structural pressure. European e-commerce volumes face margin compression from rising energy and labor costs. Logistics operators have seen volume gains partially offset by cost inflation since 2022.

The disconnect raises a direct question for equity investors: what growth rate is the market pricing in, and is it achievable?

At significant capital, the stock has already priced in an optimistic scenario. The consensus target of significant capitalprices in an even more optimistic one.1 Neither aligns with the significant capitalDCF floor.

For European equity portfolios with logistics exposure, the risk is asymmetric.Downside to DCF value is 75%.1

Valuation disconnects of this scale can persist when market liquidity is high and growth narratives dominate. They tend to compress when earnings disappoint or macro conditions tighten.

ID Logistics has not issued a profit warning. The risk is structural — a pricing model that leaves little margin for error if fundamentals reassert themselves.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com